{
  "id": 3716484,
  "title": "Why is Novo Nordisk stock sliding today?",
  "url": "https://urgent.news/2026/08/27/why-is-novo-nordisk-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-27T10:29:24.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-novo-nordisk-stock-sliding-today-93CH-4878811"
  },
  "original_language": "en",
  "account": "Novo Nordisk's stock experienced a 2.4% decline, trading at 297.8 Danish kroner following a downgrade from Deutsche Bank. Analyst Emmanuel Papadakis, citing mixed results and upcoming capital markets day uncertainties, reduced the price target from 290 to 265 kroner, moving the stock to a Sell rating from Hold. This marks one of the most bearish assessments from a major investment bank in recent times, bringing the sell-side rating distribution to five buys, eighteen holds, and two sells. The downgrade arrives amidst a challenging period since the Q2 2026 earnings release on August 4, where the stock fell despite management raising its full-year outlook, as investors focused on Wegovy's prescription trajectory falling below expectations and pipeline setbacks like the failed Ziltivekimab cardiovascular trial. A prior Berenberg downgrade to Hold on August 12 added to the pressure. Despite recovering from its 52-week low of 224.3 kroner, shares have remained below their 52-week high of 410 kroner. Competitively, Eli Lilly's widening lead in the GLP-1 obesity drug space, with its oral weight-loss treatment receiving European approval, further challenges Novo Nordisk's Wegovy franchise. The broader U.S. markets remained modestly positive, but the company-specific weaknesses highlighted by Deutsche Bank's sell rating and reduced price target have crystallized investor concerns over Novo Nordisk's near-term growth, pipeline, and competitive standing, leading to today's decline.",
  "summary": null,
  "key_points": [
    "Novo Nordisk stock down 2.4% to 297.8 DKK",
    "Deutsche Bank downgrades to Sell, reduces price target to 265 kroner",
    "Challenges include Wegovy prescription expectations and pipeline setbacks"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}